SCHEMBL2948710

SCHEMBL2948710

c1n[nH]cc1-c1cnc2ccc(NC3CCOCC3)nn12

nearest known ligand 0.72

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FYN P06241 9/20 0.72
MKNK1 Q9BUB5 2/20 0.72
PIM1 P11309 10/20 0.66
KCNH2 Q12809 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12614356 0.85 MKNK1 (0.55) FYNMKNK1PIM1KCNH2
SCHEMBL1055979 0.85 FYN (0.80) FYNMKNK1PIM1KCNH2
SCHEMBL1053282 0.84 FYN (0.73) FYNMKNK1PIM1KCNH2
SCHEMBL1055978 0.84 FYN (0.79) FYNMKNK1PIM1KCNH2
SCHEMBL3027305 0.84 FYN (1.00) FYNMKNK1PIM1KCNH2
SCHEMBL1055016 0.84 FYN (0.81) FYNMKNK1PIM1KCNH2
SCHEMBL4779099 0.83 FYN (0.79) FYNMKNK1PIM1KCNH2
SCHEMBL1051264 0.83 FYN (0.79) FYNMKNK1PIM1KCNH2
SCHEMBL1055876 0.83 FYN (0.79) FYNMKNK1PIM1KCNH2
SCHEMBL1052943 0.83 FYN (0.79) FYNMKNK1PIM1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906512-B2 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2011-03-15 US disclosed
US-7906512-B2 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2011-03-15 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20100168116-A1 3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES ALCON, INC. (CH) 2010-07-01 US disclosed
US-20100168116-A1 3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES ALCON, INC. (CH) 2010-07-01 US disclosed
US-7713975-B1 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2010-05-11 US disclosed
US-7713975-B1 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases ALCON, INC. (CH) 2010-05-11 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168116-A1 3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES SYK, IRAK3, IRAK2 FYN 34/4885MKNK1 1088/4885PIM1 588/4885
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885MKNK1 144/4885PIM1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.